jim cramer eli lilly glp 1 Wall Street is focused on these GLP-1 weight-loss drugs… how will it affect the market and how can you profit off of it? There’s one key name to watch Eli Lilly's $12.8 billion obesity

Tony Mangubat and his team believe patients deserve evidence-based guidance not hype

Supports liver health during significant weight changes

GLP-1s generally have a hefty price tag and can start at $800 or more a month, and most private insurers dont cover these medications for weight loss

Additionally, both semaglutide and tirzepatide showed promise in improving metabolic dysfunction-associated steatotic liver disease (MASLD), mitigating systemic inflammation, and contributing to improvements in liver-related outcomes, including steatosis resolution and fibrosis-related endpoints, in clinical trials

I am very satisfied with the service

Finally, its possible that obesity weakens the bodys immune system